Going-concern and financing risk
The company has no product revenue and expects to need additional capital to fund operations and commercialization.
- Scope
- Cash runway into fourth quarter 2025 under current plan
- Materiality
- high
Cingulate Inc.
Cingulate Inc. is a clinical-stage pharmaceutical company developing differentiated prescription therapies, with its lead program CTx-1301 aimed at ADHD. The company is focused on advancing its pipeline through clinical development, regulatory filing, and eventual commercialization via partnerships or outsourced sales infrastructure.
1.16
1.16
| % | |
|---|---|
| Lead drug candidate development | 70% Clinical development, manufacturing, and regulatory work for CTx-1301 and related pipeline assets. |
| Pipeline expansion and in-licensing | 15% Evaluation of new products, product candidates, and acquisitions to broaden the portfolio. |
| Commercialization partnerships | 10% Potential licensing and fee-for-service commercialization support for approved products. |
| Grant-funded development programs | 5% Externally funded clinical and manufacturing work, including CTx-2103 support. |
Cingulate does not yet sell commercial products, so its near-term counterparties are primarily clinical research...
- Pharmaceutical licensing partnersprimary
Companies that may license CTx-1301 in the U.S. or internationally to commercialize the asset.
- Clinical development vendorsprimary
CROs, investigators, and manufacturers that provide trial execution, supply, and testing services.
- Regulatory agenciesprimary
FDA and comparable authorities that review the NDA and determine approval timing.
- Future ADHD prescribers and patientsemerging
Physicians and patients who would use the product if approved, driving eventual product demand.
Cingulate is headquartered in the United States and its current development, regulatory, and commercialization planning...
- •United States is the core operating and regulatory market
- •FDA approval timing is critical to U.S. commercialization
- •Indegene services are tied to U.S. commercialization planning
- •International licensing is a potential future expansion path
- •No disclosed product revenue by country to date
Cingulate’s strategy is to complete development of CTx-1301, file the NDA, and secure a pharmaceutical partner or...
01
File the NDA for CTx-1301short-term
Regulatory submission is the key milestone needed to move the lead asset toward approval and value creation.
02
Secure a strategic pharmaceutical partnershipshort-term
A partner can provide commercialization reach and reduce the need for Cingulate to build costly sales infrastructure.
03
Fund pipeline and commercialization needsshort-term
The company needs additional capital to continue development and support launch activities if approval is obtained.
04
Broaden the product pipelinemedium-term
Adding assets through in-licensing or acquisition can diversify risk beyond a single lead program.
Cingulate is a pre-revenue clinical-stage company, so its business depends on successful trials, regulatory approval,...
Clinical and regulatory failure risk
CTx-1301 and other candidates may not achieve successful trial outcomes or FDA approval.
- Scope
- Lead asset NDA timing and approval pathway
- Materiality
- high
Commercialization execution risk
The company may rely on partners or outsourced providers for marketing, sales, market access, and distribution.
- Scope
- Indegene MSA and future licensing arrangements
- Materiality
- high
Manufacturing and supply chain risk
Clinical supply and commercial-scale manufacturing timing can affect trial progress and launch readiness.
- Scope
- CTx-1301 and CTx-2103 development
- Materiality
- medium
Key personnel retention risk
A small development-stage company depends heavily on a limited management and scientific team.
- Scope
- Management and R&D execution
- Materiality
- medium
Research and development expense accruals
Affects operating loss comparability quarter to quarter
Going-concern assessment
Important for liquidity and financial statement interpretation
Grant accounting and contingent royalty obligation
Affects cash flow, liabilities, and future commercialization economics
Future collaboration and license revenue recognition
Could materially change reported revenue once commercialization begins
: 28.4.2026